Back to today’s briefing

Story perspectives

Novo Nordisk's Amycretin Advances to Phase 3 Trials

6/13/2025

50 4

Summary

Story summary

Novo Nordisk is set to propel its promising drug, amycretin, into Phase 3 trials for weight management in early 2026. This exciting move comes after encouraging feedback from regulators, following successful mid-stage trials. With an impressive average weight loss of 22% reported in earlier studies, amycretin could be a game-changer in the fight against obesity.

1 of 1

Story summary

Novo Nordisk is set to propel its promising drug, amycretin, into Phase 3 trials for weight management in early 2026. This exciting move comes after encouraging feedback from regulators, following successful mid-stage trials. With an impressive average weight loss of 22% reported in earlier studies, amycretin could be a game-changer in the fight against obesity.